July 27, 2023—Werfen announced it has completed its acquisition of Immucor after obtaining all necessary regulatory and antitrust approvals.
Read More »Werfen to acquire Immucor
Nov. 4, 2022—Werfen announced it has agreed to acquire Immucor from asset management firm TPG.
Read More »Echo Lumena gets FDA clearance
July 2018—Immucor announced its next-generation, fully automated Echo Lumena received FDA clearance. Echo Lumena is the company’s fifth-generation benchtop immunohematology instrument, designed for small- to mid-volume laboratories.
Read More »NGS HLA typing solution, 3/16
March 2016—Immucor, in collaboration with Sirona Genomics, announced the launch of Mia Fora NGS, a high-resolution human leukocyte antigen typing solution that provides accurate, comprehensive coverage of 11 HLA genes. With a workflow that can be automated or run manually, Mia Fora NGS is adapted for use on the Illumina MiSeq next-generation sequencing platform and is available for research use only in the U.S. and other countries, with CE mark anticipated shortly.
Read More »FDA-approved molecular assay for blood transfusions, 9/14
September 2014—Immucor’s PreciseType HEA test is an FDA-approved molecular assay designed to provide clinicians and blood banks with the detailed genetic matching information they need to reduce the risk of alloimmunization and serious hemolytic reactions, which is especially problematic for patients receiving frequent blood transfusions.
Read More »